Vitaris Recalls Over 21,000 Bottles of Heart Medication

The FDA classified the recall of telmisartan and amlodipine tablets as a Class III event due to superpotency.

Updated on Oct. 21, 2026 in Heart Disease

Vitaris Recalls Over 21,000 Bottles of Heart Medication

Live Poll

Do you trust that pharmaceutical companies maintain consistent quality standards for the medications you use?

Vitaris Inc. initiated a recall of 21,600 bottles of telmisartan and amlodipine tablets on October 1, 2026. The FDA classified the action as a Class III recall because the telmisartan content in the medication exceeded established manufacturing specifications.

Why it matters

The recall addresses concerns regarding superpotency in a medication used to treat hypertension. Ensuring that active ingredients match labeled dosages is essential for patient safety and the effective management of heart-related conditions.

The recalled medication consists of 40-milligram doses of telmisartan and 5-milligram doses of amlodipine packaged in 30-count bottles. These lots, which include 3228113 through 3228121, were manufactured in India for Mylan Pharmaceuticals, Inc.

The players

Vitaris Inc.

This pharmaceutical company is responsible for the distribution and recall of the telmisartan and amlodipine tablets.

FDA

The Food and Drug Administration is the federal agency responsible for overseeing the safety and efficacy of medical products in the United States.

Mylan Pharmaceuticals, Inc.

This company is a major pharmaceutical entity that contracted the manufacturing of the recalled medication.

The details

Vitaris Inc. issued the recall after identifying that the telmisartan content was higher than specifications in specific manufacturing lots. The FDA posted the formal notice of this Class III action to its enforcement database the week of October 21, 2026.

Vitaris recalled the medication on October 1, 2026.
The FDA posted the recall notice during the week of October 21, 2026.
Lots 3228113, 3228114, and 3228115 expire on October 31, 2026.
Lots 3228120 and 3228121 expire on November 30, 2026.

The Big Picture

This recall follows the standard regulatory path established by the FDA for products that are unlikely to cause adverse health consequences. It highlights the ongoing quality control processes required for global pharmaceutical supply chains.

Patients who were prescribed this specific telmisartan and amlodipine combination should verify their bottle lot numbers against the recalled list. Consult with your healthcare provider or pharmacist regarding the safety of your current medication supply.

The takeaway

Maintaining clear communication with your pharmacist is the most reliable way to stay informed about active medication recalls. Always check your prescription packaging for expiration dates and lot numbers if you have concerns about the potency of your medication.